Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control.
Cipollone F, Chiarelli F, Davì G, Ferri C, Desideri G, Fazia M, Iezzi A, Santilli F, Pini B, Cuccurullo C, Tumini S, Del Ponte A, Santucci A, Cuccurullo F, Mezzetti A. Cipollone F, et al. Among authors: mezzetti a. Diabetologia. 2005 Jun;48(6):1216-24. doi: 10.1007/s00125-005-1750-2. Epub 2005 May 3. Diabetologia. 2005. PMID: 15868137
Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty.
Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, Fazia M, Iezzi A, Cuccurullo C, Pini B, Bucci M, Santucci A, Cuccurullo F, Mezzetti A. Cipollone F, et al. Among authors: mezzetti a. Circulation. 2003 Dec 2;108(22):2776-82. doi: 10.1161/01.CIR.0000103700.05109.0D. Epub 2003 Nov 17. Circulation. 2003. PMID: 14623801 Clinical Trial.
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.
Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. Cipollone F, et al. Among authors: mezzetti a. Circulation. 2003 Sep 2;108(9):1070-7. doi: 10.1161/01.CIR.0000086014.80477.0D. Epub 2003 Aug 11. Circulation. 2003. PMID: 12912808
Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
Santilli F, Davì G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, Patrono C. Santilli F, et al. Among authors: mezzetti a. J Am Coll Cardiol. 2006 Jan 17;47(2):391-7. doi: 10.1016/j.jacc.2005.03.079. Epub 2005 Dec 20. J Am Coll Cardiol. 2006. PMID: 16412866 Free article. Clinical Trial.
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes.
Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Cuccurullo C, et al. Among authors: mezzetti a. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23. doi: 10.1161/01.ATV.0000249630.02085.12. Epub 2006 Oct 12. Arterioscler Thromb Vasc Biol. 2006. PMID: 17038636 Clinical Trial.
COX-2: friend or foe?
Iezzi A, Ferri C, Mezzetti A, Cipollone F. Iezzi A, et al. Among authors: mezzetti a. Curr Pharm Des. 2007;13(16):1715-21. doi: 10.2174/138161207780831293. Curr Pharm Des. 2007. PMID: 17584101 Review.
300 results